{{Drugbox
| IUPAC_name = (''±'')-11-quinuclidin-3-yl-5,6-dihydrobenzo[b][1]benzazepine
| image = Quinupramine.png

<!--Clinical data-->
| tradename = 
| pregnancy_category = 
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 33 hours
| excretion = 

<!--Identifiers-->
| CAS_number = 31721-17-2
| ATC_prefix = N06
| ATC_suffix = AA23
| PubChem = 93154
| ChemSpiderID = 84098
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 29O61HFF4L
| KEGG = D07336

<!--Chemical data-->
| C=21 | H=24 | N=2 
| molecular_weight = 304.43 g/mol
}}

'''Quinupramine''' (brand names '''Kevopril''', '''Kinupril''', '''Adeprim''', '''Quinuprine''') is a [[tricyclic antidepressant]] (TCA) used in [[Europe]] for the treatment of [[major depressive disorder|depression]].<ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | page = 908 | isbn = 3-88763-075-0 | oclc = | doi = | url = https://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA1575&dq=quinupramine&as_brr=3&pg=PA908#v=onepage&q=&f=false}}</ref><ref name="isbn3-527-31058-4">{{cite book |author1=José Miguel Vela |author2=Helmut Buschmann |author3=Jörg Holenz |author4=Antonio Párraga |author5=Antoni Torrens | title = Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application | publisher = Wiley-VCH | location = Weinheim | year = 2007 | page = 248 | isbn = 3-527-31058-4 | oclc = | doi = | url = https://books.google.com/books?id=yXD4QA-Y_Z0C&lpg=PA248&dq=quinupramine&as_brr=3&pg=PA248#v=onepage&q=&f=false}}</ref>

Pharmacologically, quinupramine acts ''[[in vitro]]'' as a strong [[muscarinic acetylcholine receptor]] [[receptor antagonist|antagonist]] ([[anticholinergic]]) and [[H1 receptor|H<sub>1</sub> receptor]] [[receptor antagonist|antagonist]] ([[antihistamine]]), moderate [[5-HT2|5-HT<sub>2</sub> receptor]] [[receptor antagonist|antagonist]], and weak [[serotonin reuptake inhibitor|serotonin]] and [[norepinephrine reuptake inhibitor]].<ref name="pmid6098759">{{cite journal |vauthors=Sakamoto H, Yokoyama N, Kohno S, Ohata K | title = Receptor binding profile of quinupramine, a new tricyclic antidepressant | journal = Japanese Journal of Pharmacology | volume = 36 | issue = 4 | pages = 455–60 |date=December 1984 | pmid = 6098759 | doi = 10.1254/jjp.36.455| url = }}</ref> It has negligible affinity for the [[a1-adrenergic|α<sub>1</sub>-adrenergic]], [[a2-adrenergic|α<sub>2</sub>-adrenergic]], [[beta-adrenergic|β-adrenergic]], or [[D2 receptor|D<sub>2</sub>]] [[Receptor (biochemistry)|receptor]].<ref name="pmid6098759"/>

Clinically, quinupramine is reported to be [[stimulant|stimulating]] similarly to [[imipramine]], [[desipramine]], and [[demexiptiline]].<ref name="isbn0-306-47406-9">{{cite book |author1=Kent, Angela |author2=M. Billiard | title = Sleep: physiology, investigations, and medicine | publisher = Kluwer Academic/Plenum | location = New York | year = 2003 | page = 233 | isbn = 0-306-47406-9 | oclc = | doi = | url = https://books.google.com/books?id=IorPrIY6dOYC&lpg=PA233&dq=quinupramine&as_brr=3&pg=PA233#v=onepage&q=quinupramine&f=false}}</ref> It can be inferred that its ''[[in vivo]]'' [[metabolite]]s may have stronger effects on the reuptake of norepinephrine and/or serotonin than quinupramine itself.{{Citation needed|date=October 2014}}

==References==
{{Reflist|2}}

{{Antidepressants}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Histamine receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Dibenzazepines]]
[[Category:Muscarinic antagonists]]
[[Category:Quinuclidines]]
[[Category:Tricyclic antidepressants]]


{{nervous-system-drug-stub}}